Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Intrathecal Idursulfase in Hunter Syndrome
NCT02412787Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Apr 2024
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of idursulfase in mucopolysaccharidosis type II, sponsored by Takeda. Started Apr 2015; status: completed.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT02412787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412787.